中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

17 records (took 0.022 seconds)

    신규한 인간 엑소좀 단백질 및 그 용도
    12.
    发明公开
    신규한 인간 엑소좀 단백질 및 그 용도 无效
    一种新的人类外源性蛋白质及其使用

    公开(公告)号：KR1020140136805A

    公开(公告)日：2014-12-01

    申请号：KR1020130057331

    申请日：2013-05-21

    Applicant: 건국대학교 산학협력단

    Inventor： 정혜원 ,  박형순 ,  임현정

    IPC: C07K14/47 ,  G01N33/68

    CPC classification number: G01N33/6893 ,  G01N2800/164

    Abstract: The present invention relates to a novel human exsome protein and the use thereof. Usual exsome whose diameter is between 30 and 100nm and shape is round is a microvesicle from endosome. More specifically, the exsome in the present invention is widely used in diagnosis and treatment, so the application value thereof is recognized. In the present invention, the exsome has functions to kill cells, generate blood vessels, treat inflammation, coagulate blood and interact cells and environments and is expected to be a new cause of disease of senial macular degeneration.

    Abstract translation: 本发明涉及一种新的人外源蛋白及其用途。 直径30〜100nm，形状圆形的通常是来自内体的微泡。 更具体地，本发明中的现有技术广泛地用于诊断和治疗，因此认识到其应用价值。 在本发明中，exsome具有杀死细胞，产生血管，治疗炎症，凝结血液和相互作用的细胞和环境的功能，并且预期是老年黄斑变性疾病的新病因。

    중수소로 치환된 올리고에틸렌티올분자 및 그 제조방법
    14.
    发明公开
    중수소로 치환된 올리고에틸렌티올분자 및 그 제조방법 有权
    去离子水杨酸甘油三醇分子及其制备方法

    公开(公告)号：KR1020120073128A

    公开(公告)日：2012-07-04

    申请号：KR1020110140499

    申请日：2011-12-22

    Applicant: 건국대학교 산학협력단 ,  다이아텍코리아 주식회사

    Inventor： 여운석 ,  박형순 ,  최인성 ,  강현욱

    IPC: C07C321/08 ,  C07C315/06 ,  G01N30/72

    Abstract: PURPOSE: An oligo(ethylene thiol) molecule substituted with deuterium and a manufacturing method thereof are provided to be used for mass analysis reference substance and to be applied in various fields. CONSTITUTION: A manufacturing method of an oligo(ethylene thiol) molecule substituted with deuterium comprises the following steps: a step of synthesizing 2-(2-(hex-5-enyloxy)ethoxy)ethanol or 2-(2-(undec-10-enyloxy)ethoxy)ethanol by reacting 6-bromohexene or 11-bromoundecene with NaOH solution and dithylene glycol mixed solution; a step of synthesizing 6-(2-(2-bromoethoxy)ethoxy)hex-1-ene or 11-(2-(2-bromo-ethoxy)ethoxy)undec-1-ene by reacting triphenyl phosphine and carbon tetrabromide with the product from the previous step; a step of synthesizing 2-(2-(2-(hex-5-enyloxy)ethoxy)ethoxy)ethanol-d4 or 2-(2-(2-(undec-10-enyloxy)ethoxy)ethoxy)ethanol-d4 by reacting NaH and ethylene glycol-D4 with the product from the previous step; a step of synthesizing S-6-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)hexyl ethanethioate-d4 or S-11-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)undecyl ethanethioate by reacting thioacetic acid and 2,2'-azobis(2-methylpropionamidine)dihydrochloride with the product from the previous step; and a step of synthesizing 2-(2-(2-(6-mercaptohexyloxy)ethoxy)ethoxy) ethanol-d4 or 2-(2-(2-(11-mercaptoundecyloxy)ethoxy)ethoxy)ethanol by reacting HCl with the product from the previous step.

    Abstract translation: 目的：用氘取代的低聚（乙烯硫醇）分子及其制造方法，用于质量分析参考物质，适用于各种领域。 构成：用氘取代的低聚（乙烯硫醇）分子的制造方法包括以下步骤：合成2-（2-（己-5-烯氧基）乙氧基）乙醇或2-（2-（十一碳-10-基） - 乙氧基）乙醇通过6-溴己烯或11-溴代癸酸与NaOH溶液和二亚乙基二醇混合溶液反应; 通过使三苯基膦和四溴化碳与四溴化碳反应合成6-（2-（2-（2-溴乙氧基）乙氧基）己-1-烯或11-（2-（2-溴 - 乙氧基）乙氧基）十一-1-烯） 产品从上一步; 乙氧基）乙氧基）乙氧基）乙醇-d4或2-（2-（2-（十一碳-10-烯氧基）乙氧基）乙氧基）乙醇-d4的步骤 将NaH和乙二醇-DD与前一步骤的产物反应; 合成S-6-（2-（2-（2-羟基乙氧基）乙氧基）乙氧基）乙基硫代乙酸酯-d4或S-11-（2-（2-（2-羟基乙氧基）乙氧基）乙氧基）十一烷基乙磺酸酯的步骤 将上述步骤中的产物与硫代乙酸和2,2'-偶氮双（2-甲基丙脒）二盐酸盐反应; 和通过HCl与产物反应合成2-（2-（2-（2-（6-巯基己氧基）乙氧基）乙氧基）乙醇-d4或2-（2-（2-（2-巯基十一烷氧基）乙氧基）乙氧基）乙醇）的步骤 从上一步。

    비뉴클레오시드 계열의 Ｃ형 간염 치료 또는 예방제
    17.
    发明公开
    비뉴클레오시드 계열의 Ｃ형 간염 치료 또는 예방제 失效
    用于治疗或预防丙型肝炎的非核苷类药物

    公开(公告)号：KR1020090107926A

    公开(公告)日：2009-10-14

    申请号：KR1020090024111

    申请日：2009-03-20

    Applicant: 건국대학교 산학협력단

    Inventor： 박형순 ,  이수재 ,  정유훈 ,  김동은

    IPC: C07C59/84 ,  C07C59/48 ,  A61P1/16

    Abstract: PURPOSE: A non-nucleoside hepatitis C treating and preventing medicine is provided to exhibit high hepatitis C virus inhibition effect with few side effects. CONSTITUTION: A non-nucleoside hepatitis C treating and preventing medicine comprises a compound represented by formula 1, and its pharmacologically allowable salts. In formula 1, R1 ~ R5 are independently hydrogen or -R6-(CH2)n-R7, wherein R6 is O or NH, n is an integer between 1 and 3, and R7 is phenyl or the phenyl substituted with halogen. The compound is selected from the group consisting of 4-(4-benzyloxy-phenyl)-2-hydroxy-4-oxo-but-2-enoic acid, 4-[4-(4-chloro-benzyloxy)phenyl]-2-hydroxy-4-oxo-but-2-enoic acid, 4-(3-benzyloxy-phenyl)-2-hydroxy-4-oxo-but-2-enoic acid, 4-[3-(4-chloro-benzyl oxy)phenyl]-2-hydroxy-4-oxo-but-2-enoic acid, 4-(2-benzyloxy-phenyl)-2-hydroxy-4-oxo-but-2-enoic acid, 4-[2-(4-chloro-benzyl oxy)phenyl]-2-hydroxy-4-oxo-but-2-enoic acid, 4-(3-benzylamino-phenyl)-2-hydroxy-4-oxo-but-2-enoic acid, and 4-[3-(4-chloro-benzylamino)phenyl]-2-hydroxy-4-oxo-but-2-enoic acid.

    Abstract translation: 目的：提供非核苷类丙型肝炎治疗和预防药物，表现出高丙型肝炎病毒抑制作用，副作用少。 构成：非核苷类丙型肝炎治疗和预防药物包含由式1表示的化合物及其药理学上允许的盐。 在式1中，R 1〜R 5独立地是氢或-R 6 - （CH 2）n -R 7，其中R 6是O或NH，n是1和3之间的整数，并且R 7是苯基或被卤素取代的苯基。 该化合物选自4-（4-苄氧基 - 苯基）-2-羟基-4-氧代 - 丁-2-烯酸，4- [4-（4-氯 - 苄氧基）苯基] -2 - 羟基-4-氧代 - 丁-2-烯酸，4-（3-苄氧基 - 苯基）-2-羟基-4-氧代 - 丁-2-烯酸，4- [3-（4-氯 - 苄基 氧基）苯基] -2-羟基-4-氧代 - 丁-2-烯酸，4-（2-苄氧基 - 苯基）-2-羟基-4-氧代 - 丁-2-烯酸，4- [2- （4-氯 - 苄氧基）苯基] -2-羟基-4-氧代 - 丁-2-烯酸，4-（3-苄基氨基 - 苯基）-2-羟基-4-氧代 - 丁-2-烯酸 和4- [3-（4-氯 - 苄基氨基）苯基] -2-羟基-4-氧代 - 丁-2-烯酸。

Patent Agency Ranking